Comparative Pharmacology
Head-to-head clinical analysis: LANSOPRAZOLE AMOXICILLIN AND CLARITHROMYCIN COPACKAGED versus NEXIUM 24HR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LANSOPRAZOLE AMOXICILLIN AND CLARITHROMYCIN COPACKAGED versus NEXIUM 24HR.
LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN (COPACKAGED) vs NEXIUM 24HR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lansoprazole is a proton pump inhibitor that irreversibly inhibits the H+/K+ ATPase enzyme system (proton pump) at the secretory surface of gastric parietal cells, suppressing basal and stimulated gastric acid secretion. Amoxicillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis. Clarithromycin is a macrolide antibiotic that binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis.
Esomeprazole is a proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells. It is a weak base that accumulates in the acidic environment of the parietal cell canaliculus, where it is protonated and converted to the active achiral sulfenamide form, which forms a covalent disulfide bond with cysteine residues of the H+/K+ ATPase, irreversibly inhibiting the pump.
Each dose: Lansoprazole 30 mg, Amoxicillin 1000 mg, Clarithromycin 500 mg administered orally twice daily for 10-14 days.
20 mg orally once daily for 14 days for frequent heartburn; for gastroesophageal reflux disease (GERD), 20 mg orally once daily for 4-8 weeks; for erosive esophagitis, 20-40 mg orally once daily for 4-8 weeks.
None Documented
None Documented
Lansoprazole: ~1.5 h (prolonged in hepatic impairment); Amoxicillin: ~1-1.5 h (prolonged in renal impairment); Clarithromycin: ~3-4 h (6-9 h for 14-hydroxy metabolite).
The terminal elimination half-life is approximately 1-2 hours in healthy individuals. However, the pharmacodynamic effect (acid suppression) lasts longer due to accumulation in the parietal cell canaliculus and irreversible binding to the proton pump. In poor CYP2C19 metabolizers, half-life may extend to 3-4 hours.
Lansoprazole: primarily hepatic metabolism, ~33% renal (metabolites), ~67% fecal; Amoxicillin: ~60-80% renal unchanged; Clarithromycin: ~20-30% renal unchanged, ~50% hepatic metabolism, ~30% fecal.
Approximately 77% of a single oral dose is excreted in urine as metabolites (primarily hydroxy- and desmethyl-omeprazole) and glucuronide conjugates, with less than 1% as unchanged drug. About 19% is eliminated in feces via biliary excretion. Renal clearance accounts for the majority of elimination.
Category A/B
Category C
Proton Pump Inhibitor
Proton Pump Inhibitor